Historical AI Consensus
This page preserves the research and market snapshot packaged for this batch. It is not updated with later prices or revised advisor outputs.
- Symbol
- SLDP.NASDAQ
- Batch
- 7
- Published
- September 20, 2026
- AI Advisors
- 14
Historical AI Consensus Investment Thesis
Solid Power (SLDP) Stock Forecast and AI Rating
Forecast targets and rating
Published batch rating
BUY
Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.
1-Year
NEUTRAL$2.68
+8.5%5-Year
BUY$4.73
+91.5%Published batch insight
Sulfide Electrolyte Pure Play Bridges Automotive Valuation Chasm Through Asset Light Model
Analytical reports show sharp divergence between aggressive long-term valuation optimism and near-term commercial reality. The primary catalyst centers on industrial continuous electrolyte pilot line commissioning, while the dominant friction remains protracted automotive qualification cycles alongside relentless pre-commercial operational cash burn and ongoing equity dilution before decade-end adoption.
This analysis preserves the original published batch. Audit published forecasts in full transparency
Warren Buffett (Value Purist), Universal Investor (Polymath), Ray Dalio (Strategist), Machiavelli (Insider), Michael Burry (Vulture), Superintelligence (Anthropologist), Sherlock Holmes (Whistleblower), Elon Musk (Visionary), J.P. Morgan (Titan). Some archetypes run in multiple modes, resulting in 14 advisors total.
Gemini
Claude
ChatGPTFull published thesis
Executive Summary
If you invested $10,000 in Solid Power at publication: $19,154 in five years versus $13,892 for S&P 500 benchmark.
20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView tableClose table
Frozen forecast from 18 Sept 2026. Prices in USD; returns exclude dividends. Each quarter is compounded from the previous quarter.
Swipe the table horizontally to read every column.
| Quarter / date | Target (USD) | Quarter return | Total return | Forecast rationale |
|---|---|---|---|---|
| Q118 Dec 2026 | 2.51 | +1.50% | +1.50% | Mechanical commissioning of the continuous pilot line concludes on schedule in Colorado, providing operational reassurance. While tax-loss selling and high policy rates restrain multiple expansion, substantial balance-sheet liquidity establishes solid downside support. |
| Q218 Mar 2027 | 2.56 | +2.02% | +3.55% | Initial continuous powder output validates engineering viability, though full-year financials reflect ongoing developmental cash burn. Markets digest negligible baseline revenue while recognizing Department of Energy milestone disbursements and progress in early customer sampling. |
| Q318 Jun 2027 | 2.65 | +3.74% | +7.42% | Electrolyte sample shipments to European and Asian automotive partners demonstrate enhanced material uniformity. Modest valuation gains are tempered by macro interest rate headwinds, keeping share prices tethered to tangible balance sheet resources. |
| Q418 Sept 2027 | 2.68 | +1.03% | +8.53% | Extended automotive testing cycles and persistent operating expenditures induce seasonal consolidation. Market participants digest pre-commercial research losses while awaiting definitive term sheets for commercial joint-venture manufacturing capacity in South Korea. |
| Q518 Dec 2027 | 2.78 | +3.57% | +12.40% | Progress on Korean manufacturing agreements and positive laboratory feedback from partner cell testing provide positive fundamental momentum. Investor sentiment improves as continuous synthesis yields support higher sampling volumes heading into year-end. |
| Q618 Mar 2028 | 2.83 | +2.03% | +14.68% | Full-year reporting confirms disciplined expense control, preserving over three years of solvent operational runway. The lack of commercial off-take contracts caps speculative fervor, keeping valuation balanced between cash backing and intellectual property. |
| Q718 Jun 2028 | 2.92 | +3.12% | +18.25% | Delivery of qualification-grade sulfide electrolyte for automotive B-sample cell fabrication highlights tangible technical maturation. Demonstrating roll-to-roll manufacturing compatibility offsets concerns over elevated discount rates, prompting constructive accumulation across institutional accounts. |
| Q818 Sept 2028 | 3.01 | +3.13% | +21.96% | Automotive partner evaluations confirm solid-state thermal stability advantages over conventional liquid cells. However, broader macroeconomic deceleration and persistent research cash burn prompt orderly profit-taking across speculative clean technology equities. |
| Q918 Dec 2028 | 3.18 | +5.61% | +28.80% | Groundbreaking on commercial-scale international manufacturing infrastructure and initial non-automotive specialty sampling agreements restore upward momentum. Upfront engineering receipts and commercial visibility support multiple expansion as automotive testing enters advanced phases. |
| Q1018 Mar 2029 | 3.22 | +1.27% | +30.43% | Annual financial updates emphasize steady research overhead and extended automotive vehicle launch timelines stretching toward 2030. Investors weigh long-term licensing upside against the reality of ongoing dilution, resulting in mild valuation consolidation. |
| Q1118 Jun 2029 | 3.36 | +4.36% | +36.11% | Automotive demonstration fleet testing showcases superior low-temperature performance and fast-charging resilience. Evidence of vehicle-level durability re-energizes market interest, driving share appreciation as partners prepare production-intent solid-state vehicle platform architectures. |
| Q1218 Sept 2029 | 3.50 | +3.97% | +41.52% | Expanded continuous synthesis yields support initial commercial material shipments to niche aerospace and robotics accounts. While automotive commercialization remains pending, non-automotive revenue diversification proves unit economics and validates the capital-light licensing strategy. |
| Q1318 Dec 2029 | 3.64 | +4.26% | +47.55% | Automotive patrons advance toward binding multi-year electrolyte procurement schedules ahead of scheduled vehicle rollouts. Valuation rerates higher as contracted volume visibility replaces exploratory joint development assumptions across Wall Street models. |
| Q1418 Mar 2030 | 3.80 | +4.24% | +53.80% | Commercial-scale electrolyte production facilities initiate commissioning runs, expanding global output capacity. Although ramp-up expenses modestly elevate quarterly cash outflows, tangible industrial progress dispels lingering skepticism regarding large-scale solid-state manufacturability. |
| Q1518 Jun 2030 | 3.97 | +4.49% | +60.71% | Automotive partners publicly showcase pre-production luxury electric vehicles powered by licensed solid-state cells. High-profile validation drives retail and institutional sponsorship, pushing the equity upward as commercial market integration becomes concrete. |
| Q1618 Sept 2030 | 4.11 | +3.55% | +66.41% | First commercial-scale electrolyte shipments generate sequential top-line growth, significantly narrowing quarterly operating losses. Investors reprice the enterprise from a speculative research venture to an operational specialty chemical supplier with clear operating leverage. |
| Q1718 Dec 2030 | 4.28 | +4.17% | +73.35% | Year-end financial audits confirm accelerating materials revenue alongside initial cell licensing fees. The market absorbs minor valuation digestion as long-term multiples normalize against tangible recurring operational cash flows. |
| Q1818 Mar 2031 | 4.38 | +2.28% | +77.31% | Full-year 2030 results demonstrate marked progress toward operating cash flow breakeven. Monetary easing and declining discount rates support clean technology valuations, while multi-OEM licensing visibility shields the company from customer concentration risks. |
| Q1918 Jun 2031 | 4.59 | +4.90% | +86.00% | Serial automotive showroom deliveries commence across luxury electric vehicle lines in Europe and Asia. Compounding powder demand drives production lines toward high capacity utilization, confirming structural pricing power and expanding gross margins. |
| Q2018 Sept 2031 | 4.73 | +2.98% | +91.54% | The five-year forecast closes with the company established as a qualified upstream chemical supplier to the global battery industry. Sustained operating cash flows and protected intellectual property moats secure durable enterprise valuation support. |
The fundamental investment case rests on the asset-light economic architecture separating proprietary sulfide electrolyte synthesis and cell intellectual property licensing from ruinous gigafactory capital expenditure. While a pristine, debt-free balance sheet holding substantial liquid reserves insulates the enterprise against near-term insolvency, valuation remains hyper-sensitive to extended automotive original equipment manufacturer qualification cycles and persistent operational cash burn. The primary counterargument warns that aggressive cost deflation in mature liquid lithium-ion and sodium chemistries threatens to relegate expensive solid-state cells to luxury vehicle enclaves, permanently capping the addressable merchant volume before industrial scale materializes.
Key insights
- Continuous-flow chemical processing at the pilot facility represents the decisive inflection point for verifying industrial-scale synthesis economics and attracting binding supply commitments.
- Massive balance sheet liquidity eliminates near-term restructuring hazards, yet steady research spending gradually depreciates per-share asset backing unless non-dilutive licensing receipts accelerate.
- Multi-partner OEM alliances provide indispensable cell validation, but non-exclusive contract terms leave customer pricing power entrenched and commercial timing outside management control.
The company is building a smarter battery business by making specialty electrolyte powders and licensing designs rather than constructing multi-billion-dollar factories. Substantial cash reserves and zero debt protect the business today, but developing automotive batteries takes years of patience. The key risk is that cheaper conventional batteries keep improving, which could delay carmaker adoption and force additional share dilution before commercial sales take off.
Key insights
- Making battery powders avoids the ruinous factory building costs that crushed many clean technology rivals.
- Large liquid reserves provide years of survival, but ongoing research spending steadily consumes that cash buffer.
- Top carmaker partnerships prove technology promise, yet non-exclusive agreements delay guaranteed long-term revenue commitments.
Deep Dive
The market consensus views the enterprise as an unviable, cash-burning science experiment stranded in pre-commercial purgatory. Anchored by recent negative quarterly revenues from milestone accounting adjustments and broader electric vehicle adoption fatigue, prevailing crowd sentiment assumes mass-market solid-state vehicle commercialization remains a distant post-2030 fantasy. Consequently, outside commentary prices the equity strictly as a melting cash pile facing eventual dilutive recapitalizations.